Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | PYGM | P11217 | 3/20 | 0.53 |
| ▸ | TK2 | O00142 | 6/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659077 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL28113579 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL4192644 | 0.90 | P2RY6 (0.51) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL7137093 | 0.89 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL22992480 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL62322 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL20875706 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL22992424 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL7182936 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL31685558 | 0.87 | PYGM (0.54) | PYGMTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090307805-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V | 2009-12-10 | — | — | US | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| US-20230295694-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11725205-B2 | Methods and polynucleotides for amplifying a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-15 | — | — | US | disclosed |
| WO-2023147565-A2 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | Opentrons LabWorks Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230046363-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-1916630-A | Method for molecular and nano material based on the electric reading of concrete affair of functionalized electrode, and cmod based device | INTEL CORP (US) | 2007-02-21 | — | — | CN | disclosed |
| EP-1015643-B1 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | AGILENT TECHNOLOGIES INC (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050079505-A1 | Electronically readable microarray with electronic addressing function | AGILENT TECHNOLOGIES INC | 2005-04-14 | — | — | US | disclosed |
| US-20050069905-A1 | Detection of molecular binding events | AGILENT TECHNOLOGIES, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040248104-A1 | Methods and reagents for profiling quantities of nucleic acids | AGILENT TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20030022150-A1 | Detecting preferential bioplymers in sample; obtain nutrient broths inoculate with cells, immerse electrodes, code cells, incubate cells with substrate, monitor response, evaluate response | AGILENT TECHNOLOGIES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-6218118-B1 | MIXTURE OF NATURAL AND MASS-MODIFIED GENERIC OLIGONUCLEOTIDE PRECURSORS; USING MIXTURE AND ENZYMATIC PROCESSES TO ALTER THE LENGTH, AND THUS THE MASS, OF PRECURSORS THAT ARE COMPLEMENTARY TO TARGET NUCLEIC ACID | AGILENT TECHNOLOGIES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1015643-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | Hewlett-Packard Company (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000003038-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | HEWLETT-PACKARD COMPANY (US) | 2000-01-20 | — | — | WO | disclosed |
| US-5459243-A | Apparatus and processes for the large scale generation and transfer of diazomethane | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | LMNA 171/4885SMN1; SMN2 611/4885TSHR 3395/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | LMNA 3119/4885SMN1; SMN2 3068/4885TSHR 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.